{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:35:19Z","timestamp":1773837319616,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,11,29]],"date-time":"2013-11-29T00:00:00Z","timestamp":1385683200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s12032-013-0782-6","type":"journal-article","created":{"date-parts":[[2013,11,28]],"date-time":"2013-11-28T10:20:22Z","timestamp":1385634022000},"source":"Crossref","is-referenced-by-count":19,"title":["Functional polymorphism of CYP2B6 G15631T is associated with hematologic and cytogenetic response in chronic myeloid leukemia patients treated with imatinib"],"prefix":"10.1007","volume":"31","author":[{"given":"Yaya","family":"Kassogue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meryem","family":"Quachouh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hind","family":"Dehbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asma","family":"Quessar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Said","family":"Benchekroun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sellama","family":"Nadifi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,11,29]]},"reference":[{"key":"782_CR1","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MWN Deininger","year":"2000","unstructured":"Deininger MWN, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia Review article. Blood. 2000;96:3343\u201356.","journal-title":"Blood"},{"key":"782_CR2","first-page":"100","volume":"56","author":"E Buchdunger","year":"1996","unstructured":"Buchdunger E, Zimmermann J, Mett H, Lydon NB, Meyer T, Muller M, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996;56:100\u20134.","journal-title":"Cancer Res"},{"key":"782_CR3","doi-asserted-by":"crossref","unstructured":"Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105:2640\u201353. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15618470 .","DOI":"10.1182\/blood-2004-08-3097"},{"key":"782_CR4","doi-asserted-by":"crossref","unstructured":"O\u2019Brien SG, Guilhot F, Larson R a, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994\u20131004. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12637609 .","DOI":"10.1056\/NEJMoa022457"},{"key":"782_CR5","doi-asserted-by":"crossref","unstructured":"Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031\u20137. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11287972 .","DOI":"10.1056\/NEJM200104053441401"},{"key":"782_CR6","doi-asserted-by":"crossref","unstructured":"Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003;102:276\u201383. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12623848 .","DOI":"10.1182\/blood-2002-09-2896"},{"key":"782_CR7","doi-asserted-by":"crossref","unstructured":"Werner B, Lutz D, Br\u00fcmmendorf TH, Traulsen A, Balabanov S. Dynamics of resistance development to imatinib under increasing selection pressure: a combination of mathematical models and in vitro data. PloS One. 2011;6:1\u20138. Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=3245228&tool=pmcentrez&rendertype=abstract .","DOI":"10.1371\/journal.pone.0028955"},{"key":"782_CR8","doi-asserted-by":"crossref","unstructured":"Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22:935\u201342. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/14990650 .","DOI":"10.1200\/JCO.2004.03.050"},{"key":"782_CR9","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1124\/jpet.103.054866","volume":"307","author":"V Lamba","year":"2003","unstructured":"Lamba V, Lamba J, Yasuda K, Strom S, Davila J, Hancock ML, et al. Hepatic CYP2B6 expression : gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther. 2003;307:906\u201322.","journal-title":"J Pharmacol Exp Ther"},{"key":"782_CR10","doi-asserted-by":"crossref","unstructured":"Saarikoski ST, Rivera SP, Hankinson O, Husgafvel-Pursiainen K. CYP2S1: a short review. Toxicol Appl pharmacol. 2005;207:62\u20139. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16054184 .","DOI":"10.1016\/j.taap.2004.12.027"},{"key":"782_CR11","doi-asserted-by":"crossref","unstructured":"Gonzalez F, Crespi C, Czerwinski M, Gelbon V. Tohoku J Exp Med. 1992;168:67\u201372.","DOI":"10.1620\/tjem.168.67"},{"key":"782_CR12","doi-asserted-by":"crossref","unstructured":"Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, de Berardinis V, et al. Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics. 1999;9:295\u2013306. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10471061 .","DOI":"10.1097\/00008571-199906000-00004"},{"key":"782_CR13","doi-asserted-by":"crossref","unstructured":"Ekins S, Wrighton S a. The role of CYP2B6 in human xenobiotic metabolism. Drug Metab Rev. 1999;31:719\u201354. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10461547 .","DOI":"10.1081\/DMR-100101942"},{"key":"782_CR14","doi-asserted-by":"crossref","unstructured":"Lang T, Klein K, Fischer J, N\u00fcssler a K, Neuhaus P, Hofmann U, et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics. 2001;11:399\u2013415. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11470993 .","DOI":"10.1097\/00008571-200107000-00004"},{"key":"782_CR15","doi-asserted-by":"crossref","unstructured":"Lewis DF V. 57 varieties: the human cytochromes P450. Pharmacogenomics. 2004;5:305\u201318. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15102545 .","DOI":"10.1517\/phgs.5.3.305.29827"},{"key":"782_CR16","doi-asserted-by":"crossref","unstructured":"Villuendas R, Steegmann JL, Poll\u00e1n M, Tracey L, Granda a, Fern\u00e1ndez-Ruiz E, et al. Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach. Leukemia. 2006;20:1047\u201354. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16598311 .","DOI":"10.1038\/sj.leu.2404197"},{"key":"782_CR17","doi-asserted-by":"crossref","unstructured":"Deininger MW, O\u2019Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21:1637\u201347. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12668652 .","DOI":"10.1200\/JCO.2003.11.143"},{"key":"782_CR18","doi-asserted-by":"crossref","unstructured":"Kantarjian HM, O\u2019Brien S, Cortes J, Giles FJ, Rios MB, Shan J, et al. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer. 2003;98:2636\u201342. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/14669283 .","DOI":"10.1002\/cncr.11831"},{"key":"782_CR19","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/nar\/16.3.1215","volume":"16","author":"S Miller","year":"1988","unstructured":"Miller S, Dykes D, Polesky H. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.","journal-title":"Nucleic Acids Res"},{"key":"782_CR20","doi-asserted-by":"crossref","unstructured":"Berk\u00f6z M, Yalin S. Association of CYP2B6 G15631T polymorphism with acute leukemia susceptibility. Leuk Res. 2009;33:919\u201323. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19144407 .","DOI":"10.1016\/j.leukres.2008.11.014"},{"key":"782_CR21","doi-asserted-by":"crossref","first-page":"11937","DOI":"10.1016\/S0021-9258(17)44323-7","volume":"258","author":"DJ Waxman","year":"1983","unstructured":"Waxman DJ, Ko A, Walsh C. Regioselectivity and stereoselectivity of androgen hydroxylations catalyzed by cytochrome P-450 isozymes purified from phenobarbital-induced rat liver. J Biol Chem. 1983;258:11937\u201347.","journal-title":"J Biol Chem"},{"key":"782_CR22","doi-asserted-by":"crossref","unstructured":"Seree EJ, Pisano PJ, Placidi M, Rahmani R, Barra YA. Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism. Fundam Clin Pharmacol. 1993;7:69\u201375. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8486332 .","DOI":"10.1111\/j.1472-8206.1993.tb00219.x"},{"key":"782_CR23","doi-asserted-by":"crossref","unstructured":"Dehal SS, Kupfer D. Metabolism of the proestrogenic pesticide methoxychlor by hepatic P450 monooxygenases in rats and humans. Dual pathways involving novel ortho ring-hydroxylation by CYP2B. Drug Metab Dispos Biol Fate Chem. 1994;22:937\u201346. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7895613 .","DOI":"10.1016\/S0090-9556(25)08439-9"},{"key":"782_CR24","doi-asserted-by":"crossref","unstructured":"Evans WE, McLeod HL. Pharmacogenomics--drug disposition, drug targets, and side effects. N Engl J Med. 2003;348:538\u201349. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12571262 .","DOI":"10.1056\/NEJMra020526"},{"key":"782_CR25","doi-asserted-by":"crossref","unstructured":"Scripture CD, Sparreboom A, Figg WD. Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol. 2005;6:780\u20139. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16198984 .","DOI":"10.1016\/S1470-2045(05)70388-0"},{"key":"782_CR26","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1365-2710.2012.01340.x","volume":"37","author":"F Smires","year":"2012","unstructured":"Smires F, Moreau C, Habbal R, Siguret V, Fadili S, Golmard J, et al. Influence of genetics and non-genetic factors on acenocoumarol maintenance dose requirement in Moroccan patients. J Clin Pharm Ther. 2012;37:594\u20138.","journal-title":"J Clin Pharm Ther"},{"key":"782_CR27","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1089\/gtmb.2011.0240","volume":"16","author":"M Elmachad","year":"2012","unstructured":"Elmachad M, Elkabbaj D, Elkerch F, Laarabi F, Barkat A, Oualim Z, et al. Frequencies of CYP3A5 * 1\/* 3 variants in a Moroccan population and effect on tacrolimus daily dose requirements in renal transplant. Genet Test Mol Biomarkers. 2012;16:644\u20137.","journal-title":"Genet Test Mol Biomarkers"},{"key":"782_CR28","doi-asserted-by":"crossref","unstructured":"Belmouden A, Melki R, Hamdani M, Zaghloul K, Amraoui A, Nadifi S, et al. A novel frameshift founder mutation in the cytochrome P450 1B1 (CYP1B1) gene is associated with primary congenital glaucoma in Morocco. Clin Genet. 2002;62:334\u20139. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12372064 .","DOI":"10.1034\/j.1399-0004.2002.620415.x"},{"key":"782_CR29","doi-asserted-by":"crossref","unstructured":"Gan CQ, Wang XY, Cao YD, Ye WX, Liu H, Sun YY. Association of CYP2C19*3 gene polymorphism with breast cancer in Chinese women. Genet Mol Res GMR. 2011;10:3514\u20139. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22180071 .","DOI":"10.4238\/2011.December.5.3"},{"key":"782_CR30","unstructured":"Levkovich NN, Gorovenko NG, Myasoedov D V. Association of polymorphic G1934A variant (allele *4) of CYP2D6 gene with increased risk of breast cancer development in Ukrainian women. Exp Oncol. 2011;33:136\u20139. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21956465 ."},{"key":"782_CR31","doi-asserted-by":"crossref","unstructured":"Turpeinen M, Raunio H, Pelkonen O. The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico. Curr Drug Metab. 2006;7:705\u201314. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17073575 .","DOI":"10.2174\/138920006778520633"},{"key":"782_CR32","doi-asserted-by":"crossref","unstructured":"Waris M, White LJ. Seasonality of respiratory syncytial virus infection. Clin Infect Dis Off Publ Infect Dis Soc Am. 2006;43:541\u20132. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19713363 .","DOI":"10.1086\/505986"},{"key":"782_CR33","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1124\/jpet.107.133306","volume":"325","author":"MH Hofmann","year":"2008","unstructured":"Hofmann MH, Blievernicht JK, Klein K, Saussele T, Schaeffeler E, Schwab M, et al. Aberrant splicing caused by single nucleotide polymorphism c. 516G T [Q172H], a marker of CYP2B6 * 6, is responsible for decreased expression and activity of CYP2B6 in Liver. J Pharmacol Exp Ther. 2008;325:284\u201392.","journal-title":"J Pharmacol Exp Ther"},{"key":"782_CR34","doi-asserted-by":"crossref","unstructured":"Rakhmanina NY, van den Anker JN, Soldin SJ, van Schaik RH, Mordwinkin N, Neely MN. Can TDM improve pharmacotherapy of HIV infection in adolescents? Ther Drug Monit. 2010;32:273\u201381.","DOI":"10.1097\/FTD.0b013e3181dca14b"},{"key":"782_CR35","doi-asserted-by":"crossref","unstructured":"Xu C, Ogburn ET, Guo Y, Desta Z. Effects of the CYP2B6 * 6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo (Abstract). 2012;40:717\u201325.","DOI":"10.1124\/dmd.111.042416"},{"key":"782_CR36","doi-asserted-by":"crossref","unstructured":"Yuan Z, Liu Q, Zhang Y, Liu H, Zhao J, Zhu P. CYP2B6 gene single nucleotide polymorphisms and leukemia susceptibility. Ann Hematol. 2011;90:293\u20139. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20878158 .","DOI":"10.1007\/s00277-010-1085-z"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-013-0782-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-013-0782-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-013-0782-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:12:21Z","timestamp":1746058341000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-013-0782-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,29]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["782"],"URL":"https:\/\/doi.org\/10.1007\/s12032-013-0782-6","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,29]]},"article-number":"782"}}